Insomnia symptoms during the COVID-19 pandemic: an examination of biopsychosocial moderators.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
03 2022
Historique:
received: 13 11 2020
revised: 04 02 2021
accepted: 08 02 2021
pubmed: 5 3 2021
medline: 27 4 2022
entrez: 4 3 2021
Statut: ppublish

Résumé

Healthy sleep is vital for physical and psychological health, and poor sleep can result in a myriad of negative physical and psychological outcomes. Insomnia symptoms often manifest as a result of acute life stressors or changes, and COVID-19 experiences may be one such stressor. Other known predisposing factors to insomnia may moderate the impact of COVID-19 experiences on sleep. The present study aimed to determine current levels of insomnia severity in a US sample, to investigate the relation of COVID-19 experiences to insomnia symptoms, and to determine which individuals are most susceptible to this association. Data were drawn from a larger online survey investigating sleep and health outcomes across the lifespan. COVID-19 experiences were assessed with the exposure and impact subscales of the CAIR Pandemic Impact Questionnaire (C-PIQ). The Insomnia Severity Index (ISI) measured insomnia symptoms. Biological, psychological, and social moderators were measured using other brief self-report measures. Insomnia symptoms prevalence was as follows: moderate-to-severe symptoms (25.5%), subthreshold symptoms (37.7%), and no symptoms (36.7%). Individuals' COVID-19 experiences significantly predicted insomnia symptom severity [F(1,997) = 472.92, p < 0.001, R Although negative experiences with COVID-19 are associated with worse insomnia symptoms, this relationship is not the same for everyone.

Sections du résumé

OBJECTIVE/BACKGROUND
Healthy sleep is vital for physical and psychological health, and poor sleep can result in a myriad of negative physical and psychological outcomes. Insomnia symptoms often manifest as a result of acute life stressors or changes, and COVID-19 experiences may be one such stressor. Other known predisposing factors to insomnia may moderate the impact of COVID-19 experiences on sleep. The present study aimed to determine current levels of insomnia severity in a US sample, to investigate the relation of COVID-19 experiences to insomnia symptoms, and to determine which individuals are most susceptible to this association.
METHODS
Data were drawn from a larger online survey investigating sleep and health outcomes across the lifespan. COVID-19 experiences were assessed with the exposure and impact subscales of the CAIR Pandemic Impact Questionnaire (C-PIQ). The Insomnia Severity Index (ISI) measured insomnia symptoms. Biological, psychological, and social moderators were measured using other brief self-report measures.
RESULTS
Insomnia symptoms prevalence was as follows: moderate-to-severe symptoms (25.5%), subthreshold symptoms (37.7%), and no symptoms (36.7%). Individuals' COVID-19 experiences significantly predicted insomnia symptom severity [F(1,997) = 472.92, p < 0.001, R
CONCLUSIONS
Although negative experiences with COVID-19 are associated with worse insomnia symptoms, this relationship is not the same for everyone.

Identifiants

pubmed: 33658155
pii: S1389-9457(21)00116-7
doi: 10.1016/j.sleep.2021.02.018
pmc: PMC8364920
mid: NIHMS1678643
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-178

Subventions

Organisme : NIA NIH HHS
ID : K23 AG049955
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Depress Anxiety. 2015 Sep;32(9):664-70
pubmed: 26047492
Brain Behav Immun. 2020 Aug;88:901-907
pubmed: 32437915
Clin Geriatr Med. 2018 May;34(2):205-216
pubmed: 29661333
J Clin Sleep Med. 2020 Aug 15;16(8):1417-1418
pubmed: 32351206
Health Psychol Open. 2020 Apr 4;7(1):2055102920913235
pubmed: 32284871
Psychiatry Res. 2020 Aug;290:113134
pubmed: 32505030
Curr Psychiatry Rep. 2018 Aug 9;20(9):69
pubmed: 30094679
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
Sleep Med. 2016 Aug;24:109-118
pubmed: 27810176
Sleep Health. 2017 Oct;3(5):383-388
pubmed: 28923198
Int J Cardiol. 2016 Sep 15;219:231-9
pubmed: 27336192
J Sleep Res. 2020 Aug;29(4):e13052
pubmed: 32246787
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
Psychiatry Res. 2020 Jul;289:113076
pubmed: 32434093
J Clin Psychol. 2020 Oct;76(10):1972-1983
pubmed: 32410237
Perspect Psychol Sci. 2011 Jan;6(1):3-5
pubmed: 26162106
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Br J Health Psychol. 2012 May;17(2):420-31
pubmed: 22106955
Psychiatry Res. 2020 Aug;290:113128
pubmed: 32563951
Sleep Med. 2010 May;11(5):470-8
pubmed: 20388566
Sleep. 2007 Mar;30(3):274-80
pubmed: 17425223
Psychiatry Res. 2021 Jan;295:113599
pubmed: 33285346
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Psychiatr Clin North Am. 1987 Dec;10(4):541-53
pubmed: 3332317

Auteurs

Joseph M Dzierzewski (JM)

Department of Psychology, Virginia Commonwealth University, United States. Electronic address: dzierzewski@vcu.edu.

Natalie D Dautovich (ND)

Department of Psychology, Virginia Commonwealth University, United States.

Scott G Ravyts (SG)

Department of Psychology, Virginia Commonwealth University, United States.

Elliottnell Perez (E)

Department of Psychology, Virginia Commonwealth University, United States.

Pablo Soto (P)

Department of Psychology, Virginia Commonwealth University, United States.

Emily K Donovan (EK)

Department of Psychology, Virginia Commonwealth University, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH